Blueprint Medicines Corp (BPMC)

followers · Follow

Sector:	HEALTH CARE
Industry:	BIOTECHNOLOGY & LIFE SCIENCES
SIC:	PHARMACEUTICAL PREPARATIONS
CEO:	Kathryn Haviland
Employees:	640
Web site:	blueprintmedicines.com
45 SIDNEY STREET, CAMBRIDGE, MA, 02139 617-374-7580

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.

Please log in first to see chart

Blueprint Medicines Corp YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available